Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neurology · Autosomal Recessive Spastic Paraplegia 89

Biology & Getting the Right Diagnosis

At a Glance

SPG89 is confirmed when genetic testing finds disease-causing AMFR variants on both copies of the gene. MRI and blood or urine tests help look for other causes, but an MRI scan by itself cannot diagnose SPG89.

Diagnosing a rare condition like SPG89 is often a process of clinical evaluation—ruling out more common conditions before confirming the genetic cause. Because the symptoms of SPG89 often overlap with other neurological disorders, reaching a definitive diagnosis requires a combination of clinical observation, specialized imaging, and advanced genetic testing [1][2].

The Biology: What’s Happening in the Cells?

To understand SPG89, it helps to look at the “machinery” inside your child’s cells. The AMFR gene provides instructions for a protein that helps maintain the endoplasmic reticulum (ER), a structure that acts like a factory for producing and packaging proteins and fats [1].

In children with SPG89, variants in this gene disrupt the way the cell manages lipids (fats) [1].

  • Lipid Droplets: Research models have shown that without a working AMFR protein, cells begin to accumulate “clumps” of fat called lipid droplets [1].
  • ER Structure: The shape and function of the ER become altered, which can stress the cell [1].
  • Nerve Damage: These cellular issues are hypothesized to be particularly hard on the corticospinal tracts—the long nerves that run from the brain to the legs. Over time, these nerves struggle to function, leading to the characteristic stiffness and weakness of the condition [1][3].

Confirming the Diagnosis

The definitive method for identifying SPG89 is genetic testing. This is typically done through:

  • Multigene Panels: A blood test that looks at hundreds of genes known to cause hereditary spastic paraplegia simultaneously [4].
  • Whole-Exome Sequencing (WES): A more comprehensive test that “spells out” all the protein-coding regions of the DNA. This is often used when panels do not provide an answer [5]. Note that a negative panel does not automatically exclude SPG89, as certain structural variants might require other testing methods.

A diagnosis is confirmed when a child has two disease-causing (pathogenic or likely pathogenic) variants in the AMFR gene on opposite copies of the gene (in trans) [1][6]. A “variant of uncertain significance” (VUS) does not establish the diagnosis. Because it is an autosomal recessive condition, parents are usually unaffected “carriers” who each passed one mutated copy to their child [1].

Genetic Counseling: Parental testing is often used to establish phase (that the variants came from each parent). A genetic counselor should discuss the results, testing for other relatives, and the typical 25% recurrence risk in each pregnancy for carrier parents.

Ruling Out “Mimics”

Because SPG89 is so rare, it is frequently confused with other conditions. Your doctor will likely work to evaluate the following:

  • Cerebral Palsy (CP): CP is caused by a nonprogressive disturbance to the developing brain. However, a genetic disorder and CP-like motor impairment can sometimes coexist, and progressive symptoms do not by themselves completely rule out CP, as CP function can change due to growth, pain, and contractures [7][8].
  • Treatable Metabolic Disorders: This is a critical step. A specialist should evaluate for conditions like rare, severe MTHFR deficiency (which is distinct from common, usually benign MTHFR gene polymorphisms), biotinidase deficiency, or arginase deficiency, which can have specific treatments [9][10]. Doctors use blood and urine tests to ensure these are not the cause [11].
  • Leukodystrophies: These are other genetic conditions that affect the “white matter” (the insulation) of the brain [12].

The Role of MRI

A brain MRI (Magnetic Resonance Imaging) is a tool in the diagnostic process to assess the nervous system and exclude other causes [13]. While an MRI alone cannot diagnose SPG89—and not every person needs repeated imaging—it can show “clues.”

  • Corpus Callosum: Doctors sometimes look for a thinning of this structure, which connects the two halves of the brain [13][14].
  • White Matter Changes: Subtle changes in the brain’s white matter are sometimes seen in HSP [15].
  • Spinal Cord: In some cases, the MRI may show thinning (atrophy) of the spinal cord [16].

These are non-specific findings rather than expected diagnostic clues for SPG89, and they guide further genetic testing [13].

Common questions in this guide

What genetic result confirms SPG89?
SPG89 is confirmed when testing identifies pathogenic or likely pathogenic variants in both copies of the AMFR gene. The variants are usually shown to be on opposite gene copies, with one inherited from each parent; a variant of uncertain significance alone does not confirm the condition.
Can a negative gene panel rule out SPG89?
No. Some DNA changes may not be detected by a standard multigene panel, so clinicians may consider whole-exome or whole-genome sequencing and other methods when suspicion remains.
What can an MRI show in a child being evaluated for SPG89?
An MRI cannot diagnose SPG89 by itself. It may show nonspecific findings such as thinning of the corpus callosum, white-matter changes, or spinal cord thinning, and it can help doctors look for other causes.
What other conditions are checked before diagnosing SPG89?
Doctors may check for severe MTHFR deficiency, biotinidase deficiency, and arginase deficiency, as well as leukodystrophies and other neurological conditions. Severe MTHFR deficiency is different from common MTHFR gene polymorphisms, and blood or urine tests can help identify some treatable metabolic disorders.
What does SPG89 inheritance mean for parents?
A child develops SPG89 when they inherit a disease-causing AMFR variant from each parent. Parents are usually healthy carriers, and when both parents carry an AMFR variant, each pregnancy has a 25% chance of being affected.
What symptoms should I report to my child's neurologist?
Share when motor delays, leg stiffness, or weakness began and whether they are changing over time. Also mention possible additional concerns such as vision changes or unusual fatigue, because the neurologist will use the full symptom history when evaluating your child.

Get notified when new evidence is published on spastic paraplegia 89, autosomal recessive.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    AMFR dysfunction causes autosomal recessive spastic paraplegia in human that is amenable to statin treatment in a preclinical model.

    Deng R, Medico-Salsench E, Nikoncuk A, et al.

    Acta neuropathologica 2023; (146(2)):353-368 doi:10.1007/s00401-023-02579-9.

    PMID: 37119330
  2. 2

    Genotypic and Phenotypic Profile of Hereditary Spastic Paraplegia in Children: A Single-Centre Study from Northern India.

    Das N, Shambhavi A, Sait H, et al.

    Indian pediatrics 2026; doi:10.1007/s13312-026-00403-7.

    PMID: 42490029
  3. 3

    Childhood-onset hereditary spastic paraplegia: at the crossroads between neurodevelopment and neurodegeneration.

    Espasandin-Hueter N, Salazar-Villacorta A, Escudero JM, et al.

    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2026; (65()):50-65 doi:10.1016/j.ejpn.2026.10.002.

    PMID: 42976539
  4. 4

    Clinical and genetic spectra of 1550 index patients with hereditary spastic paraplegia.

    Méreaux JL, Banneau G, Papin M, et al.

    Brain : a journal of neurology 2022; (145(3)):1029-1037 doi:10.1093/brain/awab386.

    PMID: 34983064
  5. 5

    Increased Diagnostic Yield of Spastic Paraplegia with or Without Cerebellar Ataxia Through Whole-Genome Sequencing.

    Kim A, Kumar KR, Davis RL, et al.

    Cerebellum (London, England) 2019; (18(4)):781-790 doi:10.1007/s12311-019-01038-0.

    PMID: 31104286
  6. 6

    Experience in the clinical and genetic diagnosis of a series of Algerian patients with hereditary spastic paraplegias.

    Messaoud-Khelifi M, Boulariah-Hadjou R, Kediha MI, et al.

    Neurogenetics 2025; (26(1)):52 doi:10.1007/s10048-025-00833-8.

    PMID: 40560206
  7. 7

    Hereditary spastic paraplegia: a practical approach.

    Bradley M, Kalfat A, Walsh RA, et al.

    Practical neurology 2026; doi:10.1136/pn-2026-005344.

    PMID: 42816178
  8. 8

    The genetic etiology in cerebral palsy mimics: The results from a Greek tertiary care center.

    Zouvelou V, Yubero D, Apostolakopoulou L, et al.

    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2019; (23(3)):427-437 doi:10.1016/j.ejpn.2019.02.001.

    PMID: 30799092
  9. 9

    Inherited metabolic diseases mimicking hereditary spastic paraplegia (HSP): a chance for treatment.

    Teive HAG, Camargo CHF, Pereira ER, et al.

    Neurogenetics 2022; (23(3)):167-177 doi:10.1007/s10048-022-00688-3.

    PMID: 35397036
  10. 10

    Arginase 1 Deficiency in Patients Initially Diagnosed with Hereditary Spastic Paraplegia.

    McNutt MC, Foreman N, Gotway G

    Movement disorders clinical practice 2023; (10(1)):109-114 doi:10.1002/mdc3.13612.

    PMID: 36698992
  11. 11

    Treatable cause of hereditary spastic paraplegia: eight cases of combined homocysteinaemia with methylmalonic aciduria.

    Wei Y, Zhou Y, Yuan J, et al.

    Journal of neurology 2019; (266(10)):2434-2439 doi:10.1007/s00415-019-09432-8.

    PMID: 31203424
  12. 12

    Genetic origin of patients having spastic paraplegia with or without other neurologic manifestations.

    Chen J, Zhao Z, Shen H, et al.

    BMC neurology 2022; (22(1)):180 doi:10.1186/s12883-022-02708-z.

    PMID: 35578252
  13. 13

    Systematic Analysis of Brain MRI Findings in Adaptor Protein Complex 4-Associated Hereditary Spastic Paraplegia.

    Ebrahimi-Fakhari D, Alecu JE, Ziegler M, et al.

    Neurology 2021; (97(19)):e1942-e1954 doi:10.1212/WNL.0000000000012836.

    PMID: 34544818
  14. 14

    Hereditary spastic paraplegia type 11: Clinicogenetic lessons from 339 patients.

    Du J

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2021; (85()):67-71 doi:10.1016/j.jocn.2020.11.036.

    PMID: 33581793
  15. 15

    "Ears of the Lynx" MRI Sign Is Associated with SPG11 and SPG15 Hereditary Spastic Paraplegia.

    Pascual B, de Bot ST, Daniels MR, et al.

    AJNR. American journal of neuroradiology 2019; (40(1)):199-203 doi:10.3174/ajnr.A5935.

    PMID: 30606727
  16. 16

    Neuroimaging patterns in paediatric onset hereditary spastic paraplegias.

    Dosi C, Pasquariello R, Ticci C, et al.

    Journal of the neurological sciences 2021; (425()):117441 doi:10.1016/j.jns.2021.117441.

    PMID: 33866115

This page explains SPG89 biology and diagnostic testing for informational purposes only and does not constitute medical advice. A pediatric neurologist, medical geneticist, or genetic counselor should interpret your child's genetic results and MRI.